U.S. subsidiary for Exiqon

Exiqon (Copenhagen, Denmark) reported the adoption of the name Exiqon Diagnostics for its U.S. subsidiary to signal the company's commitment to expanding its business to a broad offering in molecular and cellular-based diagnostics that guide treatment decisions in oncology.

The company says that this change will demonstrate the continuity of the Exiqon organization and is an important symbol of Exiqon's commitment to transform Oncotech from its leading position in chemotherapy resistance testing to being the leader in personalized cancer diagnostics with a broad menu of molecular and cellular based assays for solid tumor diagnostics.

"We are excited to adopt this name for our business, as it will show to our customers and their patients that Oncotech is undergoing a positive transformation that will lead to a more valuable and comprehensive offering," said President/CEO Lars Kongsbak.

No Comments